Show simple item record

Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

hal.structure.identifierInstitut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
dc.contributor.authorCALMELS, Nadège
hal.structure.identifierBiomolécules et innovation thérapeutique [IGLBIT]
hal.structure.identifierCentre d'Etudes Nucléaires de Bordeaux Gradignan [CENBG]
dc.contributor.authorSEZNEC, Hervé
hal.structure.identifierBiomolécules et innovation thérapeutique [IGLBIT]
dc.contributor.authorVILLA, Pascal
hal.structure.identifierInstitut de génétique et biologie moléculaire et cellulaire [IGBMC]
dc.contributor.authorREUTENAUER, Laurence
hal.structure.identifierInstitut Gilbert-Laustriat : Biomolécules, Biotechnologie, Innovation Thérapeutique
dc.contributor.authorHIBERT, Marcel
hal.structure.identifierInstitut Gilbert-Laustriat : Biomolécules, Biotechnologie, Innovation Thérapeutique
dc.contributor.authorHAIECH, Jacques
hal.structure.identifierPhysiopathologie, conséquences fonctionnelles et neuroprotection des atteintes du cerveau en développement
dc.contributor.authorRUSTIN, Pierre
hal.structure.identifierInstitut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC]
dc.contributor.authorKOENIG, Michel
hal.structure.identifierInstitut de génétique et biologie moléculaire et cellulaire [IGBMC]
dc.contributor.authorPUCCIO, Hélène
dc.date.issued2009
dc.identifier.issn1471-2377
dc.description.abstractEnBACKGROUND: Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common recessive ataxia, results from a generalized deficiency of mitochondrial and cytosolic iron-sulfur cluster (ISC) proteins activity, due to a partial loss of frataxin function, a mitochondrial protein proposed to function as an iron-chaperone for ISC biosynthesis. In the absence of measurable catalytic function for frataxin, a cell-based assay is required for HTS assay. METHODS: Using a targeted ribozyme strategy in murine fibroblasts, we have developed a cellular model with strongly reduced levels of frataxin. We have used this model to screen the Prestwick Chemical Library, a collection of one thousand off-patent drugs, for potential molecules for FRDA. RESULTS: The frataxin deficient cell lines exhibit a proliferation defect, associated with an ISC enzyme deficit. Using the growth defect as end-point criteria, we screened the Prestwick Chemical Library. However no molecule presented a significant and reproducible effect on the proliferation rate of frataxin deficient cells. Moreover over numerous passages, the antisense ribozyme fibroblast cell lines revealed an increase in frataxin residual level associated with the normalization of ISC enzyme activities. However, the ribozyme cell lines and FRDA patient cells presented an increase in Mthfd2 transcript, a mitochondrial enzyme that was previously shown to be upregulated at very early stages of the pathogenesis in the cardiac mouse model. CONCLUSION: Although no active hit has been identified, the present study demonstrates the feasibility of using a cell-based approach to HTS for FRDA. Furthermore, it highlights the difficulty in the development of a stable frataxin-deficient cell model, an essential condition for productive HTS in the future.
dc.language.isoen
dc.publisherBioMed Central
dc.title.enLimitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.
dc.typeArticle de revue
dc.identifier.doi10.1186/1471-2377-9-46
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]
bordeaux.journalBMC Neurology
bordeaux.page46
bordeaux.volume9
bordeaux.peerReviewedoui
hal.identifierinserm-00420798
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//inserm-00420798v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Neurology&rft.date=2009&rft.volume=9&rft.spage=46&rft.epage=46&rft.eissn=1471-2377&rft.issn=1471-2377&rft.au=CALMELS,%20Nad%C3%A8ge&SEZNEC,%20Herv%C3%A9&VILLA,%20Pascal&REUTENAUER,%20Laurence&HIBERT,%20Marcel&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record